Literature DB >> 31776467

Extramedullary multiple myeloma.

Manisha Bhutani1, David M Foureau2, Shebli Atrash1, Peter M Voorhees1, Saad Z Usmani3.   

Abstract

Extramedullary multiple myeloma (EMM) is an aggressive subentity of multiple myeloma, characterized by the ability of a subclone to thrive and grow independent of the bone marrow microenvironment, resulting in a high-risk state associated with increased proliferation, evasion of apoptosis and treatment resistance. Despite improvement in survival for most patients with multiple myeloma over recent decades, outcomes are generally poor when EMM develops. Understanding the molecular underpinnings leading to homing of plasma cells in ecosystems outside the bone marrow will be crucial for therapeutically manipulating the microenvironment and targeting key signaling pathways. Herein, we discuss the evolutionary biology of EMM, underscore the importance of a uniform definition, discuss prognostic significance, and provide current and emerging treatment strategies for managing this rare subentity of multiple myeloma.

Entities:  

Mesh:

Year:  2019        PMID: 31776467     DOI: 10.1038/s41375-019-0660-0

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  101 in total

1.  Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases.

Authors:  Leo Rasche; Corinna Bernard; Max S Topp; Markus Kapp; Johannes Duell; Carmen Wesemeier; Eugenia Haralambieva; Uwe Maeder; Hermann Einsele; Stefan Knop
Journal:  Ann Hematol       Date:  2012-07       Impact factor: 3.673

2.  Extraskeletal spread in multiple plasma cell myeloma. A review of 57 autopsied cases.

Authors:  M W Pasmantier; H A Azar
Journal:  Cancer       Date:  1969-01       Impact factor: 6.860

3.  Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.

Authors:  Saad Z Usmani; Christoph Heuck; Alan Mitchell; Jackie Szymonifka; Bijay Nair; Antje Hoering; Yazan Alsayed; Sarah Waheed; Sajjad Haider; Alejandro Restrepo; Frits Van Rhee; John Crowley; Bart Barlogie
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

Review 4.  Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach.

Authors:  Joan Bladé; Carlos Fernández de Larrea; Laura Rosiñol; María Teresa Cibeira; Raquel Jiménez; Ray Powles
Journal:  J Clin Oncol       Date:  2011-09-06       Impact factor: 44.544

Review 5.  Extravasation and homing mechanisms in multiple myeloma.

Authors:  Isabelle Vande Broek; Karin Vanderkerken; Benjamin Van Camp; Ivan Van Riet
Journal:  Clin Exp Metastasis       Date:  2007-10-19       Impact factor: 5.150

6.  Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia.

Authors:  Hong Chang; Xiaoying Qi; Joanna Yeung; Donna Reece; Wei Xu; Bruce Patterson
Journal:  Leuk Res       Date:  2008-08-03       Impact factor: 3.156

Review 7.  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Authors:  C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah
Journal:  Leukemia       Date:  2012-11-21       Impact factor: 11.528

Review 8.  Extramedullary multiple myeloma.

Authors:  Matthew Weinstock; Irene M Ghobrial
Journal:  Leuk Lymphoma       Date:  2012-12-31

Review 9.  How I treat extramedullary myeloma.

Authors:  Cyrille Touzeau; Philippe Moreau
Journal:  Blood       Date:  2015-12-17       Impact factor: 22.113

10.  Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns.

Authors:  Ingrid Cifola; Marta Lionetti; Eva Pinatel; Katia Todoerti; Eleonora Mangano; Alessandro Pietrelli; Sonia Fabris; Laura Mosca; Vittorio Simeon; Maria Teresa Petrucci; Fortunato Morabito; Massimo Offidani; Francesco Di Raimondo; Antonietta Falcone; Tommaso Caravita; Cristina Battaglia; Gianluca De Bellis; Antonio Palumbo; Pellegrino Musto; Antonino Neri
Journal:  Oncotarget       Date:  2015-07-10
View more
  47 in total

1.  Lung Nodule in a Patient with Multiple Myeloma.

Authors:  William C Harding; Mathieu Marcoux; Roberto F Casal; Lara Bashoura; John Stewart; Hans C Lee; Saadia A Faiz
Journal:  Am J Respir Crit Care Med       Date:  2020-11-15       Impact factor: 21.405

Review 2.  MRD Assessment in Multiple Myeloma: Progress and Challenges.

Authors:  Luca Bertamini; Mattia D'Agostino; Francesca Gay
Journal:  Curr Hematol Malig Rep       Date:  2021-05-05       Impact factor: 3.952

3.  Comparison of clinical characteristics, treatment efficacy and survival in patients with newly diagnosed multiple myeloma with single- versus multi-site extramedullary invasion.

Authors:  Yongfeng Zhao; Fuling Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-25       Impact factor: 4.553

Review 4.  Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma.

Authors:  Linda Heimberg; Stefan Knop
Journal:  Oncol Res Treat       Date:  2021-11-18       Impact factor: 2.825

Review 5.  Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.

Authors:  Michael Heider; Katharina Nickel; Marion Högner; Florian Bassermann
Journal:  Oncol Res Treat       Date:  2021-11-08       Impact factor: 2.825

6.  Sustained remission of giant pancreatic plasmacytoma with daratumumab.

Authors:  Satoshi Ichikawa; Eijiro Furukawa; Kei Saito; Noriko Fukuhara; Koichi Onodera; Yasushi Onishi; Hisayuki Yokoyama; Ryo Ichinohasama; Hideo Harigae
Journal:  Ann Hematol       Date:  2020-06-18       Impact factor: 3.673

7.  Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.

Authors:  Tomas Jelinek; Tereza Sevcikova; David Zihala; Tereza Popkova; Veronika Kapustova; Lucie Broskevicova; Lenka Capkova; Lucie Rihova; Renata Bezdekova; Sabina Sevcikova; Vladimir Zidlik; Martin Havel; Hana Plonkova; Alexandra Jungova; Jiri Minarik; Martin Stork; Ludek Pour; Petr Pavlicek; Ivan Spicka; Vladimir Maisnar; Jakub Radocha; Michal Simicek; Roman Hajek
Journal:  Leukemia       Date:  2021-07-10       Impact factor: 11.528

8.  PET/CT F18-FDG with soft tissue plasmacytomas in multiple myeloma.

Authors:  Alejandro Martí; Sarai Morón; Sandra Chinchilla; Eliana González
Journal:  Eur J Hybrid Imaging       Date:  2021-03-31

9.  Intratumor Heterogeneity of MIF Expression Correlates With Extramedullary Involvement of Multiple Myeloma.

Authors:  Juan Xu; Nanhui Yu; Pan Zhao; Fangfang Wang; Jingcao Huang; Yushan Cui; Hong Ding; Yan Yang; Yuhan Gao; Ling Pan; Hong Chang; Yu Wu; Bing Xiang; Yuping Gong; Xiao Shuai; Li Hou; Liping Xie; Ting Niu; Ting Liu; Li Zhang; Weiping Liu; Wenyan Zhang; Ying Qu; Wei Lin; Yimin Zhu; Sha Zhao; Yuhuan Zheng
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

10.  Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma.

Authors:  JingSong He; XiaoYan Yue; DongHua He; Yi Zhao; Yang Yang; GaoFeng Zheng; Enfan Zhang; XiaoYan Han; WenJun Wu; Li Yang; Jing Chen; Zhen Cai
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.